research use only

Denifanstat (TVB-2640) Fatty Acid Synthase inhibitor

Name: Denifanstat (TVB-2640)
Brand: Selleck Chemicals
SKU: S9714
Availability: InStock
Rating: 5 (13 reviews)

Cat.No.S9714

Denifanstat (TVB-2640) is an orally bioavailable, pharmacological fatty acid synthase (FAS/FASN) inhibitor with therapeutic potential in patients with NAFLD and nonalcoholic steatohepatitis.

Denifanstat (TVB-2640) Fatty Acid Synthase inhibitor Chemical Structure

Quality Control

Batch: Purity: 99.98%

99.98

Related Targets	Dehydrogenase HSP Transferase P450 (e.g. CYP17) PDE phosphatase PPAR Vitamin Carbohydrate Metabolism Mitochondrial Metabolism
Other Fatty Acid Synthase Inhibitors	Fatostatin TVB-3664 C75 Betulin FT113 C75 trans Sodium palmitate IPI-9119 Desoxyrhaponticin Praeruptorin B

Solubility

In vitro
Batch:

DMSO : 88 mg/mL (200.2 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 88 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	4.400mg/ml (10.01mM)	Taking the 1 mL working solution as an example, add 50 μL 88 mg/ml clarified DMSO stock solution to 400 μL PEG300, mix evenly to clarify it; add 50 μL Tween80 to the above system, mix evenly to clarify it; then continue to add 500 μL ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	439.55	Formula	C₂₇H₂₉N₅O	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	1399177-37-7	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	ASC-40, FASN-IN-2			SMILES	CC1=NN=C([NH]1)C2=C(C=C(C)C(=C2)C(=O)N3CCC(CC3)C4=CC=C(C=C4)C#N)C5CCC5

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	FAS
In vitro	Denifanstat (TVB-2640) markedly inhibits SARS-CoV-2 with EC50s of 4 nM, and could strikingly inhibit SARS-CoV-2 new variants with similar inhibitory effects on the early-lineage SARS-CoV-2 (USA-WA1/2020) virus.
In vivo	Denifanstat (TVB-2640) shows significant in vivo antiviral activity and protects SARS-CoV-2-infected mice for survival.
References	[1] https://pubmed.ncbi.nlm.nih.gov/31630414/ [2] https://pubmed.ncbi.nlm.nih.gov/34580494/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2025-05-15)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06594523	WITHDRAWN	MASH; NASH; Metabolic Dysfunction-associated Steatohepatitis; Noncirrhotic Metabolic Dysfunction-associated Steatohepatitis; Nonalcoholic Steatohepatitis; Nonalcoholic Fatty Liver	Sagimet Biosciences Inc.	2025-03	PHASE3
NCT05743621	RECRUITING	Prostatic Neoplasms, Castration-Resistant	Weill Medical College of Cornell University	2023-11-20	PHASE1
NCT06692283	WITHDRAWN	MASLD; MASH; NASH; Metabolic Dysfunction-Associated Steatotic Liver Disease; Metabolic Dysfunction-Associated Steatohepatitis; Nonalcoholic Steatohepatitis; Nonalcoholic Fatty Liver	Sagimet Biosciences Inc.	2025-03	PHASE3
NCT06248008	COMPLETED	Acne	Ascletis Pharmaceuticals Co., Ltd.	2024-04-18	PHASE3
NCT07216313	COMPLETED	Healthy	Sagimet Biosciences Inc.	2025-09-30	PHASE1
NCT06192264	COMPLETED	Acne	Ascletis Pharmaceuticals Co., Ltd.	2024-01-23	PHASE3

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):